Diabetic Neuropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Feb. 22, 2011 - PRLog -- GlobalData’s analysis suggests that the global DN market was worth $1.41 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.5% for the next seven years, to reach $2.49 billion by 2017. This is primarily attributed to the increase in the prevalence of the disease and the strong pipeline with new first-in-class therapies.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Diabetic-Neuropathy-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

GlobalData analyzed the current competitive landscape for DN drugs and found that the competition is moderate to weak. There are only two FDA (Food and Drug Administration) approved products which are Cymbalta (duloxetine) from Eli Lilly and Lyrica (pregabalin) from Pfizer but these are targeting diabetic neuropathy pain only. In addition, gabapentin and amitriptyline are also used as off label drugs for the treatment of pain associated with diabetic neuropathy. Generics such as topical capsaicin are also used but such products do not hold a major share in the market. The other available drug classes for the treatment of the pain associated with DN are antidepressants, antiepileptics, opioids and NSAIDs (Non-Steroidal Anti-Inflammatory Drug). The competition is weak due to a lack of competing products for Cymbalta and Lyrica. The market has a huge potential for molecules with better safety and efficacy profile and especially such molecules targeting disease progression and offering a cure for DN.

The global diabetic neuropathy therapeutics market is attractive, with high unmet need. This unmet need in the market is around 41%, which is approximately valued at $0.58 billion. The unmet need is due to the lack of availability of effective treatment options targeting disease progression, difficulties in diagnosis and the moderate safety profile of the marketed drugs. The efficacy of the marketed products is moderate. The current treatment options focus on symptomatic relief and are only moderately efficacious. The DN market offers opportunity for newer disease modifying treatment options.

GlobalData, the industry analysis specialist, has released its new report, “Diabetic Neuropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global diabetic neuropathy market. The report identifies the key trends shaping and driving the global diabetic neuropathy market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global diabetic neuropathy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Diab...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.